Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251394 · ClinicalTrials.gov registry record · Phase 2
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00251394 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT00251394, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effects (good and bad) and the safety of Dynavax's immunostimulatory phosphorothiolate oligodeoxyribonucleotide (1018 ISS) given in combination with Rituxan on patients with B-cell follicular non-Hodgkin's lymphoma. This research is being done because recurrent follicular non-Hodgkin's lymphoma is not curable with standard chemotherapy or antibody treatments. 1018 ISS is an experimental compound that consists of short pieces of DNA that stimulate the immune system. It is hoped that 1018 ISS may improve the ability of Rituxan to kill cancer cells.
Interventions
- DRUG Rituxan
- DRUG 1018 ISS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251394
The ClinicalTrials.gov registry entry for NCT00251394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituxan is the first listed.
NCT00251394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251394 about?
NCT00251394 is a clinical study titled "Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma". The main purpose of this study is to determine the effects (good and bad) and the safety of Dynavax's immunostimulatory phosphorothiolate oligodeoxyribonucleotide (1018 ISS) given in combination with Rituxan on patients with B-cell follicular non-Hodgkin's lymphoma. This research is being done becau...
What is the current status of trial NCT00251394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00251394?
The interventions under investigation include: Rituxan (DRUG), 1018 ISS (DRUG).
Who is sponsoring clinical trial NCT00251394?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.